Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4.
Moore, James V
Waller, Michael L
McGown, Alan T
Hadfield, John A
Pettit, G R
Pettit, G R
Hastings, David L
AffiliationNorth West Medical Physics, Christie Hospital (NHS) Trust, Manchester, UK.
MetadataShow full item record
AbstractThere are major potential advantages in non-invasive measurement of preclinical tumour biology and therapeutic response in clinically relevant, internal body sites, notably the ability to follow outcome in individual animals rather than averaging results from groups. We have exploited positron emission tomography (PET) to determine the feasibility of detecting liver metastases in B6D2F1 mice using fluorine-18 fluorodeoxyglucose ([18F]FDG) both before and after treatment by the novel cytotoxic agent, combretastatin A-4. The normal distribution of [18F]FDG in the absence of disease was characterised, with the clear delineation of the brain, the heart and the urinary bladder in all studies. In untreated mice with liver metastases, a strong correlation (r2 = 0.98) was found between the quantitative estimates of [18F]FDG uptake obtained by analysis of PET images, and those obtained from ex vivo assay of liver plus metastases excised immediately after imaging. In this first series, the effective limit of resolution was in livers containing a number of small metastases (range 8-14) with a single volume equivalent of approximately 200 mm3. PET image analysis was concordant with histological measurements in showing that single intraperitoneal doses of combretastatin A-4 resulted in an average 30% volume destruction of metastatic mass by 24 h following administration.
CitationPositron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. 1999, 26 (3):231-8 Eur J Nucl Med
JournalEuropean Journal of Nuclear Medicine
- Feasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography.
- Authors: Moore JV, Waller ML, Zhao S, Dodd NJ, Acton PD, Jeavons AP, Hastings DL
- Issue date: 1998 Sep
- More advantages in detecting bone and soft tissue metastases from prostate cancer using <sup>18</sup>F-PSMA PET/CT.
- Authors: Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE
- Issue date: 2019 Jan-Apr
- PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
- Authors: Goshen E, Davidson T, Zwas ST, Aderka D
- Issue date: 2006 Feb
- Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
- Authors: Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, Pratt B, Husband J, Flower M, Ott R
- Issue date: 1996 Mar
- 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
- Authors: Bienert M, McCook B, Carr BI, Geller DA, Sheetz M, Tutor C, Amesur N, Avril N
- Issue date: 2005 Jul